RA
LCTX icon

Raffles Associates’s Lineage Cell Therapeutics LCTX Stock Holding History

Raffles Associates’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.81M Sell
5,197,788
-165,000
-3% -$228K 5.8% 5
2026
Q1 		$8.47M Hold
5,362,788
– – 7.35% 2
2025
Q4 		$8.96M Sell
5,362,788
-25,000
-0.5% -$43.3K 6.72% 4
2025
Q3 		$9.11M Sell
5,387,788
-4,300
-0.1% -$5.09K 8.48% 2
2025
Q2 		$4.89M Sell
5,392,088
-250,000
-4% -$148K 5.1% 7
2025
Q1 		$2.55M Buy
5,642,088
+150,000
+3% +$88K 3.1% 10
2024
Q4 		$2.76M Buy
5,492,088
+984,307
+22% +$723K 2.97% 12
2024
Q3 		$4.08M Buy
4,507,781
+150,000
+3% +$139K 4.19% 9
2024
Q2 		$4.35M Buy
4,357,781
+1,147,800
+36% +$1.27M 4.9% 8
2024
Q1 		$4.75M Buy
3,209,981
+1,078,360
+51% +$1.22M 5.51% 6
2023
Q4 		$2.32M Buy
2,131,621
+543,882
+34% +$596K 2.94% 10
2023
Q3 		$1.87M Sell
1,587,739
-10,000
-0.6% -$13.6K 2.48% 14
2023
Q2 		$2.25M Buy
1,597,739
+60,793
+4% +$84K 3.03% 10
2023
Q1 		$2.31M Hold
1,536,946
– – 3.14% 11
2022
Q4 		$1.8M Sell
1,536,946
-543,590
-26% -$685K 2.1% 13
2022
Q3 		$2.35M Buy
2,080,536
+150,000
+8% +$220K 2.51% 11
2022
Q2 		$3.05M Buy
1,930,536
+624,441
+48% +$823K 3.32% 10
2022
Q1 		$2.01M Buy
1,306,095
+762,505
+140% +$1.18M 2.07% 13
2021
Q4 		$1.33M Buy
543,590
+450,000
+481% +$1.05M 1.28% 19
2021
Q3 		$236K Buy
93,590
+50,000
+115% +$128K 0.22% 39
2021
Q2 		$124K Hold
43,590
– – 0.11% 43
2021
Q1 		$102K Buy
+43,590
New +$105K 0.1% 36
2018
Q3 		– Sell
-51,435
Closed -$93K – 52
2018
Q2 		$93K Buy
+51,435
New +$104K 0.08% 50

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Raffles Associates's LCTX Position: Q2 2026 in Review

Raffles Associates reduced its Lineage Cell Therapeutics (LCTX) stake by 3.1% in Q2 2026, selling an estimated $228K and leaving 5,197,788 shares worth $6.81M. The position accounts for 5.8% of the portfolio, ranked #5.

Raffles Associates first reported a position in LCTX in Q2 2018 and has held it in 23 quarters since. The position peaked at $9.11M in Q3 2025. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • Raffles Associates held 5,197,788 shares of Lineage Cell Therapeutics worth $6.81M as of Q2 2026.
  • Raffles Associates sold 165,000 Lineage Cell Therapeutics shares in Q2 2026, an estimated $228K.
  • Lineage Cell Therapeutics made up 5.8% of Raffles Associates's portfolio in Q2 2026, its #5 holding.
  • Raffles Associates first reported a position in Lineage Cell Therapeutics in Q2 2018 and has held it in 23 quarters since.
  • Raffles Associates's Lineage Cell Therapeutics position peaked at $9.11M in Q3 2025.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Raffles Associates's 13F filing for Q2 2026, filed 14 Aug 2026.